Filtered By:
Cancer: Bone Cancers
Drug: Tetracycline

This page shows you your search results in order of date.

Order by Relevance | Date

Total 3 results found since Jan 2013.

MYC overexpression leads to increased chromatin interactions at super-enhancers and MYC binding sites RESEARCH
The MYC oncogene encodes for the MYC protein and is frequently dysregulated across multiple cancer cell types, making it an attractive target for cancer therapy. MYC overexpression leads to MYC binding at active enhancers, resulting in a global transcriptional amplification of active genes. Because super-enhancers are frequently dysregulated in cancer, we hypothesized that MYC preferentially invades into super-enhancers and alters the cancer genome organization. To that end, we performed ChIP-seq, RNA-seq, circular chromosome conformation capture (4C-seq), and Spike-in Quantitative Hi-C (SIQHiC) on the U2OS osteosarcoma ce...
Source: Genome Research - April 8, 2022 Category: Genetics & Stem Cells Authors: See, Y. X., Chen, K., Fullwood, M. J. Tags: RESEARCH Source Type: research

MYC overexpression leads to increased chromatin interactions at superenhancers and MYC binding sites RESEARCH
The MYC oncogene encodes for the MYC protein and is frequently dysregulated across multiple cancer cell types, making it an attractive target for cancer therapy. MYC overexpression leads to MYC binding at active enhancers, resulting in a global transcriptional amplification of active genes. Since superenhancers are frequently dysregulated in cancer, we hypothesized that MYC preferentially invades into superenhancers and alters the cancer genome organization. To that end, we performed ChIP-seq, RNA-seq, 4C-seq and SIQHiC (Spike-in Quantitative Hi-C) on the U2OS osteosarcoma cell line with tetracycline-inducible MYC. MYC ove...
Source: Genome Research - February 3, 2022 Category: Genetics & Stem Cells Authors: See, Y. X., Chen, K., Fullwood, M. J. Tags: RESEARCH Source Type: research